Loading...
Please wait, while we are loading the content...
Similar Documents
Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent.
Content Provider | Semantic Scholar |
---|---|
Author | Abizaid, Alexandre Antônio Da Cunha Lansky, Alexandra J. Fitzgerald, Peter J. Tanajura, Luis Fernando Leite Feres, Fausto Staico, Rodolfo Mattos, Luiz Alberto Piva E Abizaid, Andrea Claudia Leão De Souza Chaves, Áurea Jacob Centemero, Marinella Patrizia Sousa, Amanda Guerra Morais Rego Sousa, J. Eduardo Morais Rego Zaugg, Margo J. Schwartz, Lewis B. |
Copyright Year | 2007 |
Abstract | The ZoMaxx Coronary Stent System elutes the antiproliferative agent zotarolimus via a biocompatible phosphorylcholine polymer loaded onto a novel, thin, stainless steel stent platform containing an 0.0007-inch inner layer of tantalum that enhances fluoroscopic radiopacity. The objective of this single-arm prospective clinical trial was to assess the safety and performance of the ZoMaxx stent for the treatment of coronary artery stenosis. Forty consecutive patients with ischemic coronary occlusive disease due to single de novo obstructive lesions of native coronary arteries were treated with 3 x 18 mm ZoMaxx stents at the Dante Pazzanese de Cardiologie in Saõ Paulo, Brazil, between April and July 2005. Independent core laboratories analyzed quantitative coronary angiography and intravascular ultrasound results immediately after stent implantation, and after 4 months. The lesion, procedure, and device-deployment success rates were all 100% (40 of 40). There were no major adverse cardiac events during the study. Follow-up quantitative coronary angiography at 4 months revealed in-stent and in-segment late lumen losses of 0.20 +/- 0.35 and 0.17 +/- 0.35 mm, respectively. Follow-up intravascular ultrasound at 4 months revealed 6.5 +/- 6.2% neointimal volume obstruction. There were no instances of late acquired stent incomplete apposition or stent thrombosis. In conclusion, the ZoMaxx Coronary Stent can be safely implanted for the treatment of de novo coronary artery stenosis. The inhibition of neointima formation as measured by follow-up angiography and IVUS after 4 months suggests therapeutic potential for the reduction of restenosis. |
Starting Page | 47 |
Ending Page | 52 |
Page Count | 6 |
File Format | PDF HTM / HTML |
Alternate Webpage(s) | http://www.lewisbschwartz.com/uploads/2/4/6/6/24662586/zomaxx_ivus_abizaid_ajc_2007.pdf |
PubMed reference number | 17493469v1 |
Volume Number | 99 |
Issue Number | 10 |
Journal | The American journal of cardiology |
Language | English |
Access Restriction | Open |
Subject Keyword | Arterial stenosis Coronary Artery Disease Coronary Stenosis Deploy Implants Intravascular ultrasound Laboratory Metal-on-Metal Joint Prostheses Neointima Obstruction Patients Phosphorylcholine Polymers Quantitative Coronary Angiography Stainless Steel Stent Device Component Stent, device Structure of lumen of body system Tantalum Thrombosis angiogram coronary revascularization restenosis zotarolimus |
Content Type | Text |
Resource Type | Article |